Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Aptevo Therapeutics (APVO) Cost of Revenue (2016 - 2019)

Aptevo Therapeutics' Cost of Revenue history spans 5 years, with the latest figure at $6.1 million for Q4 2019.

  • For Q4 2019, Cost of Revenue changed N/A year-over-year to $6.1 million; the TTM value through Dec 2019 reached $19.9 million, changed N/A, while the annual FY2019 figure was $19.9 million, 77.7% up from the prior year.
  • Cost of Revenue for Q4 2019 was $6.1 million at Aptevo Therapeutics, up from $4.0 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $6.5 million in Q2 2016 and bottomed at $488000.0 in Q1 2017.
  • The 5-year median for Cost of Revenue is $4.3 million (2018), against an average of $4.1 million.
  • The largest annual shift saw Cost of Revenue plummeted 86.17% in 2017 before it soared 264.96% in 2018.
  • A 5-year view of Cost of Revenue shows it stood at $5.2 million in 2015, then fell by 3.0% to $5.1 million in 2016, then crashed by 62.68% to $1.9 million in 2017, then grew by 28.53% to $2.4 million in 2018, then surged by 151.78% to $6.1 million in 2019.
  • Per Business Quant, the three most recent readings for APVO's Cost of Revenue are $6.1 million (Q4 2019), $4.0 million (Q3 2019), and $6.0 million (Q2 2019).